Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies999
Clover Biopharmaceuticals
Clover Biopharmaceuticals is a clinical-stage biotech company focused on developing vaccines and biologic therapeutics.
Sector
Subsector
Keywords
Location
total rounds
total raised
Heat Biologics
Heat Biologics is a biopharmaceutical company focused on developing therapies to modulate the immune system.
Sector
Subsector
Location
total rounds
total raised
Sonnet BioTherapeutics
Sonnet BioTherapeutics is a biotechnology company that develops innovative targeted biologic drugs using its proprietary FHAB™ technology.
Sector
Subsector
Keywords
Location
total rounds
total raised
Inhibrx
Inhibrx is a biotech company focused on developing optimized biologic therapeutics for life-threatening conditions.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds16
Number of Funding Rounds
Money Raised
Their latest funding was raised on 16.05.2023. Their latest round Post-IPO Equity
Pharmakon Advisors
Pharmakon Advisors is a NY investment firm for biotech companies seeking financing.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors18
Number of lead investors
Number of investors
Armentum Partners
Armentum Partners is a financial services firm specializing in debt capital solutions.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Pharmakon Advisors
Pharmakon Advisors is a NY investment firm for biotech companies seeking financing.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Lilly Ventures
Lilly Ventures is the venture capital arm of Eli Lilly and Company, focusing on life science investments in North America and Europe.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
S. Edward Torres
Acquisitions2
Surface Oncology acquired by Coherus Biosciences
acquirer
date
price
Surface Oncology
Surface Oncology is a clinical-stage immuno-oncology company developing next-generation therapies to help cancer patients.
Sector
Subsector
Keywords
Location
total rounds
total raised
InteKrin acquired by Coherus Biosciences
acquirer
date
type
price
InteKrin
InteKrin Therapeutics develops and commercializes therapeutics for neuroendocrine, metabolic and immune disorders.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders1
Stephen C. Glover
Mr. Glover has over 30 years of business experience in biopharmaceuticals and life sciences. Currently Mr. Glover is Co-Founder and CEO of Variant Pharmaceuticals. Before founding Variant, Mr. Glover was Co-Founder of Coherus Biosciences where he was focused on the business strategy, partnerships, product development efforts and capitalization of the company. Prior to Coherus, he was the President of Insmed Therapeutic Proteins, a biosimilar company, as well as Chief Business Officer of Insmed Incorporated. Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. At Andrx Mr. Glover was responsible for the strategy and operation of Andrx Labs which developed and marketed products in metabolic diseases and Men's Health and Andrx Therapeutics which was focused on the development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health. Mr. Glover has multifaceted experience in Fortune 100, start up and entrepreneurial environments. He has demonstrated results in start ups, large cap and turnarounds with a focus on business strategy, commercial execution, product development, business transformation and corporate development. He has over 25 life sciences transactions totaling over $10 billion in licensing and M&A activities and has raised over $200M in capital. His strategic and operational experience includes strategic planning, corporate development, operations management, product development, product marketing and sales management. Currently Mr. Glover serves on the Board of Directors of Variant Pharmaceuticals and InflamaCORE. Additionally Mr. Glover serves as an Executive in Residence at the University of Miami U Innovation Life Sciences Office.
current job
Stephen C. Glover
Employee Profiles21
Lee Mermelstein
Executive Vice President Manufacturing
Erik D. Wiberg
Executive Vice President, Corporate Development
Activity
Recent News13
The graph reveals the ratio (%) of positive news articles in a chosen time range